Brief: First Wave BioPharma Finalizes Selection Of Adrulipase Microgranule Drug Delivery Formulation
07/09/2022 12:11
Sept 7 (Reuters) - First Wave BioPharma Inc FWBI.O :
* FIRST WAVE BIOPHARMA FINALIZES SELECTION OF ADRULIPASE
MICROGRANULE DRUG DELIVERY FORMULATION
* FIRST WAVE BIOPHARMA INC - FIRST WAVE BIOPHARMA EXPECTS TO
INITIATE PHASE 2 TRIAL INVESTIGATING "OPTIMIZED ADRULIPASE"
PRIOR TO YEAR-END 2022
Source text for Eikon: ID:nGNX4xWDZ8
Further company coverage: FWBI.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on GridAI Technologies
See all newsBrief: Gridai Technologies Corp - Enters $2.54 Million Private Placement Of Shares And Warrants - SEC Filing
Brief: IBN Announces Latest Episode Of The Techmediawire Podcast Featuring Marshall Chapin, CEO Of Grid Ai Corp.
Brief: Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately - SEC Filing
Brief: Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock
Brief: Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement